The STAR*D trial: revealing the need for better treatments.
about
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathwayAntidepressant mechanism of ketamine: perspective from preclinical studiesNeurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidenceThe mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stressAntidepressant treatment history as a predictor of response to scopolamine: clinical implications.Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets.Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.Lipid correlates of antidepressant response to omega-3 polyunsaturated fatty acid supplementation: A pilot study.Identifying phronotypes in psychiatry.Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies.The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey.Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good.Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to ScopolamineBaseline mood-state measures as predictors of antidepressant response to scopolamine.Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.Treatment of Major Depressive Disorder with Iyengar Yoga and Coherent Breathing: A Randomized Controlled Dosing Study.A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.Perspectives on depression--past, present, future(a).Improving late life depression and cognitive control through the use of therapeutic video game technology: A proof-of-concept randomized trial.Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the Flinders Sensitive Line rat: a genetic rodent model of depression.Treatment of Major Depressive Disorder with Iyengar Yoga and Coherent Breathing: A Randomized Controlled Dosing Study.Psychiatric tertiary referral and clinical decision making.Development of a Mobile Clinical Prediction Tool to Estimate Future Depression Severity and Guide Treatment in Primary Care: User-Centered Design.Mechanisms of ketamine action as an antidepressant.Convergent Mechanisms Underlying Rapid Antidepressant Action.
P2860
Q21559605-D2ED3FDD-579E-4311-82DF-09DA838287A8Q26800231-70664938-43FB-42EA-AD49-C7B28CBA6492Q26999061-A1C25516-7544-47C5-979B-2D5C6BC58CADQ30651146-6B3A3022-39FA-4CC1-A99D-75A1C84A6FE3Q33647744-B61F5022-3175-4AE3-8524-752DF34E7B92Q33874459-BA78B114-3914-43BB-BA33-446023139235Q34315128-D5121B33-4E44-4897-833F-3A6A0D4E6FA3Q34333515-B2DB30C2-0E62-4B86-905E-096E75C1633EQ34356083-D3F62FAF-0B0E-41E3-90E9-3B42910816A3Q34445122-6E896BCF-26F0-447E-8C16-64143A0359CFQ34555244-BD202528-5094-4C3A-9ABB-7FB8BC7B6FD9Q34689379-A3D4231F-A7C3-4C5C-8086-C344D6A0F7E6Q35109175-2BCA3BEB-C99D-45FB-A568-D88B0956D3D2Q35281480-06B3331D-CEC2-47EF-9B7B-3C8F0C0A3706Q35596249-A8BDDF69-5FDE-40C6-8D73-7600C234B686Q35736898-4A259EF5-CC53-4D90-BE64-27EAFBD74B2FQ35907475-AB50A6C5-0EB7-4586-B882-2911413FDE06Q36064491-BBFBA3C3-3444-48BB-B563-8E53CA93733EQ36296905-2FCF4217-824B-49D8-8AAD-3E2538F589BFQ36593835-4CE70656-056F-4E51-9FE4-8D3C3186EA77Q37029596-26D87BB0-F246-4AC7-9EFC-CB6C3F284833Q37713091-8D4BC1AD-756C-4C09-98C0-40C3A68D2BCBQ37713743-CD0E497D-F3B7-4D63-9485-A4951BE305EDQ38503676-22888ACC-07AC-451A-BF65-134CC81E57B3Q38774881-8E53BF70-E5D2-42C9-82C6-8472A497376AQ39756450-C73EE6F8-D332-47DD-BB58-1FCA0B3B1355Q47100237-1536E662-F94D-4D67-A44F-5A1FC6824D4AQ50665532-9090B7BC-4B6C-4169-A174-D83EDE387670Q52568777-FFD072DB-9DEB-47FA-8D7D-B3F99951AAD8Q52658612-986D9E80-52AF-4F69-BCF0-EA412682AC7DQ52667723-E1084E7F-82DB-4F47-BD85-548CC1A8B7D0
P2860
The STAR*D trial: revealing the need for better treatments.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The STAR*D trial: revealing the need for better treatments.
@ast
The STAR*D trial: revealing the need for better treatments.
@en
The STAR*D trial: revealing the need for better treatments.
@nl
type
label
The STAR*D trial: revealing the need for better treatments.
@ast
The STAR*D trial: revealing the need for better treatments.
@en
The STAR*D trial: revealing the need for better treatments.
@nl
prefLabel
The STAR*D trial: revealing the need for better treatments.
@ast
The STAR*D trial: revealing the need for better treatments.
@en
The STAR*D trial: revealing the need for better treatments.
@nl
P1433
P1476
The STAR*D trial: revealing the need for better treatments.
@en
P2093
Philip S Wang
Thomas R Insel
P304
P356
10.1176/PS.2009.60.11.1466
P577
2009-11-01T00:00:00Z